Business Daily from THE HINDU group of publications
Friday, Jun 15, 2007
ePaper


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Industry & Economy - Pharmaceuticals
NPPA fixes prices for eight non-scheduled drugs

Our Bureau

Some of these drugs, according to analysts, are "big brands".

New Delhi June 14 The National Pharma Pricing Authority has fixed the prices of eight non-scheduled drugs including Nicholas Piramal's big-selling paediatric syrup, Phenergan, Ranbaxy's antibiotic, Roscillin and an anti-infective from Novartis.

Some of these drugs, according to analysts, are "big brands". Quoting ORG IMS data, the NPPA says it has observed an increase of more than 20 per cent in prices for these drugs during the period from February 2004 to February 2005, and decided to notify the companies. The companies, which include Lupin, Lyka and Mumbai-based Meyer, had been asked to provide reasons for the price increase. But the NPPA, unsatisfied with the reasons, has under Para 10 (B) of the Drug (Price Control) Order, 1995 fixed prices for the eight formulations. The new prices have been put up on the Authority's Web site.

The companies have been given 15 days' time to issue a price list in Form V in accordance with the provisions of paragraph 15 of DPCO, 1995. The drugs whose prices have been fixed are nutrition tablets Jointace from Meyer Health Care and Meyer Organics (at a maximum retail price of Rs 84.84), Normaxin (at Rs 18.68 per ampoule or vial) from Systopic Laboratories, Rablet IV Injections (at Rs 57.40 per vial) from Lyka Labs and Lupin. Ranbaxy's antibiotic Roscillin 500 capsules (at Rs 66.77 for eight), insulin sensitiser or supplement for diabetics — Pioz (at Rs 61.92 for a strip of 10) from USV Ltd are also on NPPA's list.

Andhra Pradesh-based Greesha Labs' Ulcikit (Rs 43.34 for a strip of six), and Urclar tablets (Rs 99.84 for four) from both Ind-Swift and Novartis, and Nicholas Piramal's anti-allergic Phenergan Syrup (Rs 22.96 for 60 ml) are also included.

The NPPA in March revised the allowed increase in prices from 20 per cent annually to 10 per cent a year for non-scheduled formulations.

However, the drugs in question were judged according to the 20 per cent limit.

More Stories on : Pharmaceuticals | Regulatory Bodies & Rulings

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Kharif coverage trails in cereals, maize, oilseeds


`Sorghum-based ethanol will not impact food security'
Rising rupee: The causes and consequences
Core sector set to ride power addition
AP health project gets Rs 320-cr UK aid
NPPA fixes prices for eight non-scheduled drugs
Talent retention tops HR priorities in pharma industry
Birla School of Management
SMOT launches PG course
Special focus on agro sector in Kerala policy
`Realty prices may dip 7-10% in six months'
DLF issue subscribed 3.45 times
Centre to fund leather unit at CLC
Knitwear trade team finds Uzbekistan offers attractive
Serum Institute tops again in biotech exports
AP hints at GM seeds Act to control Bt cottonseed activity
BEL components for ISRO
InterfaceFLOR setting up arm
Role of corporates in social development stressed
The Hindu Opportunities Fair at Vizag
FBT payment on ESOPs extended to Sept 15
FICCI helping farmers get EurepGAP certification


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line